Bull Harbor Capital LLC Invests $585,000 in Stryker Corporation $SYK

Bull Harbor Capital LLC bought a new stake in shares of Stryker Corporation (NYSE:SYK) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund bought 1,779 shares of the medical technology company’s stock, valued at approximately $585,000.

Other large investors also recently made changes to their positions in the company. Norges Bank acquired a new position in Stryker in the 4th quarter valued at approximately $1,822,272,000. Auto Owners Insurance Co boosted its position in Stryker by 35,047.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock valued at $1,024,444,000 after purchasing an additional 2,906,448 shares during the last quarter. Wellington Management Group LLP grew its stake in Stryker by 22.6% in the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after purchasing an additional 1,198,665 shares in the last quarter. Corient Private Wealth LLC raised its stake in shares of Stryker by 104.4% during the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after purchasing an additional 1,146,998 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of Stryker by 241.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,555,638 shares of the medical technology company’s stock valued at $511,167,000 after buying an additional 1,100,673 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on SYK. JPMorgan Chase & Co. dropped their price objective on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Citigroup decreased their target price on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. Wells Fargo & Company dropped their price target on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. BTIG Research set a $371.00 price target on shares of Stryker in a report on Monday, July 13th. Finally, Truist Financial reaffirmed a “hold” rating and issued a $330.00 price objective (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $393.39.

Stryker Stock Down 1.1%

Shares of Stryker stock opened at $348.37 on Friday. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $401.99. The stock has a market capitalization of $133.55 billion, a P/E ratio of 40.32, a PEG ratio of 2.26 and a beta of 0.77. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The stock has a 50 day moving average price of $317.08 and a two-hundred day moving average price of $334.98.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. Stryker’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts expect that Stryker Corporation will post 14.99 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is currently 40.74%.

Insider Activity at Stryker

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This represents a 30.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 323,264 shares of company stock worth $100,659,489 in the last ninety days. 4.60% of the stock is currently owned by insiders.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker reported second-quarter adjusted earnings of $3.69 per share, ahead of estimates ranging from $3.46 to $3.49 and up from $3.13 a year earlier. Revenue reached $6.59 billion, narrowly exceeding expectations and increasing 9.4% year over year. Stryker Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Strong demand for implants and devices used in complex spinal and orthopedic procedures supported the quarterly results, indicating resilient underlying demand for Stryker’s medical technology products. Stryker Beats Quarterly Estimates on Strong Demand
• Positive Sentiment: Management provided full-year 2026 EPS guidance of $14.95 to $15.10, broadly above the current analyst consensus of approximately $14.98, supporting expectations for continued earnings growth.
• Positive Sentiment: UBS initiated coverage with a Buy rating and a $400 price target, implying meaningful upside from recent trading levels and adding a new bullish analyst view. UBS Initiates Stryker Coverage
• Neutral Sentiment: Stryker reported approximately $1.28 billion in profit and said it is making progress recovering from a March cyberattack. However, the recovery remains an operational consideration for investors. Stryker Logs Higher Profit Amid Cyberattack Recovery
• Negative Sentiment: Medical-product companies continue to face potential margin pressure from tariffs and inflation. That concern may temper the market’s reaction to Stryker’s earnings beat, particularly given the stock’s elevated valuation.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.